Department of Clinical Science and.
Pulmonary Department and.
Ann Am Thorac Soc. 2024 Sep;21(9):1261-1271. doi: 10.1513/AnnalsATS.202312-1027OC.
The definition of the lower limit of normal (LLN) of spirometric variables is not well established. To investigate the relationship between spirometric abnormalities defined with different thresholds of the LLN and clinical outcomes and to explore the possibility of using different LLN thresholds according to the pretest probability of disease. We studied the associations between prebronchodilator spirometric abnormalities (forced expiratory volume in the first second [FEV] < LLN, forced vital capacity [FVC] < LLN, airflow obstruction, spirometric restriction) defined with different thresholds of the LLN (10th, 5th, 2.5th, 1st percentile) and multiple outcomes (prevalence of spirometric abnormalities, respiratory symptoms, all-cause and respiratory mortality) in 26,091 30- to 46-year-old men who participated in a general population survey in Norway in 1988-1990 and were followed for 26 years. Analyses were performed with both local and Global Lung Function Initiative (GLI)-2012 reference equations, stratified by pretest risk (presence or absence of respiratory symptoms), and adjusted for age, body mass index, smoking, and education. In the total population, the prevalence of airflow obstruction was 11.6% with GLI-LLN10, 11.0% with Local-LLN5, 6.1% with GLI-LLN5, 7.6% with Local-LLN2.5, and 3.5% with GLI-LLN2.5. The prevalence of spirometric restriction was 5.9% with GLI-LLN10, 5.2% with Local-LLN5, and 2.8% with GLI-LLN5. Increasingly lower thresholds of the LLN were associated with increasingly higher odds of respiratory symptoms and hazard of mortality for all spirometric abnormalities with both reference equations. Spirometric abnormalities defined with Local-LLN2.5 in asymptomatic subjects were associated with lower hazard of all-cause mortality (hazard ratio [HR], 1.50; 95% confidence interval [CI], 1.15-1.95 for FEV < LLN) than those defined with Local-LLN5 in the general population (HR, 1.67; 95% CI, 1.50-1.87 for FEV < LLN) and symptomatic subjects (HR, 1.67; 95% CI, 1.46-1.91 for FEV < LLN). Overall, the prevalence of spirometric abnormalities and associations with outcomes obtained with Local-LLN5 were comparable to those obtained with GLI-LLN10 and those obtained with Local-LLN2.5 to GLI-LLN5. There is a relationship between statistically based thresholds of the LLN of spirometric variables and clinical outcomes. Different thresholds of the LLN may be used in different risk subgroups of subjects, but the choice of the threshold needs to be evaluated together with the choice of reference equations.
肺量测定变量的下限正常值(LLN)的定义尚未明确。本研究旨在探讨使用不同 LLN 界值定义的肺量测定异常与临床结局之间的关系,并探索根据疾病的先验概率使用不同 LLN 界值的可能性。我们研究了在挪威于 1988-1990 年进行的一项一般人群调查中,26091 名 30 至 46 岁男性中,使用不同 LLN 界值(第 10、5、2.5 和 1 百分位)定义的支气管扩张前肺量测定异常(第一秒用力呼气量[FEV]<LLN、用力肺活量[FVC]<LLN、气流阻塞、肺量测定受限)与多种结局(肺量测定异常的患病率、呼吸症状、全因和呼吸死亡率)之间的关系。采用本地和全球肺功能倡议(GLI)-2012 参考方程进行分析,按先验风险(有无呼吸症状)分层,并根据年龄、体重指数、吸烟和教育程度进行调整。在总人群中,GLI-LLN10 时气流阻塞的患病率为 11.6%,Local-LLN5 时为 11.0%,GLI-LLN5 时为 6.1%,Local-LLN2.5 时为 7.6%,GLI-LLN2.5 时为 3.5%。GLI-LLN10 时肺量测定受限的患病率为 5.9%,Local-LLN5 时为 5.2%,GLI-LLN5 时为 2.8%。LLN 的界值越低,与两种参考方程下所有肺量测定异常的呼吸症状发生率和死亡率危险比(HR)越高。在无症状人群中,Local-LLN2.5 定义的肺量测定异常与全因死亡率的危险比(HR,1.50;95%置信区间[CI],1.15-1.95,FEV<LLN)低于 Local-LLN5 定义的肺量测定异常(HR,1.67;95%CI,1.50-1.87,FEV<LLN)和有症状人群(HR,1.67;95%CI,1.46-1.91,FEV<LLN)。总体而言,Local-LLN5 获得的肺量测定异常的患病率和与结局的相关性与 GLI-LLN10 获得的患病率和相关性相当,而 Local-LLN2.5 与 GLI-LLN5 获得的相关性相当。肺量测定变量的 LLN 统计界值与临床结局之间存在关联。可以在不同的受试者风险亚组中使用不同的 LLN 界值,但需要结合参考方程的选择来评估界值的选择。